4.2. Analysis.
Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Development of severe symptoms according to WHO scale (≥ 5, incl. death)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.